Clinical Review
State of the Art Review
Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications
BMJ 2018; 361 doi: https://doi.org/10.1136/bmj.k1036 (Published 23 April 2018) Cite this as: BMJ 2018;361:k1036Related articles
- Research Published: 11 January 2011; BMJ 342 doi:10.1136/bmj.c7086
See more
- Advances in management of heart failureBMJ April 10, 2024, 385 e077025; DOI: https://doi.org/10.1136/bmj-2023-077025
- Effectiveness and safety of drugs for obesityBMJ March 25, 2024, 384 e072686; DOI: https://doi.org/10.1136/bmj-2022-072686
- Management of chronic pancreatitisBMJ February 26, 2024, 384 e070920; DOI: https://doi.org/10.1136/bmj-2023-070920
- Advances in diagnosis and treatment of bladder cancerBMJ February 12, 2024, 384 e076743; DOI: https://doi.org/10.1136/bmj-2023-076743
- New advances in type 1 diabetesBMJ January 26, 2024, 384 e075681; DOI: https://doi.org/10.1136/bmj-2023-075681
Cited by...
- No sign of elevated cardiovascular risk in patients with seropositive rheumatoid arthritis who remain on stable antirheumatic therapy: results from the nationwide Norwegian Cardio-Rheuma Register
- Long-term mortality in treated-to-target RA and UA: results of the BeSt and IMPROVED cohort
- Comorbidities and chance of remission in patients with early rheumatoid arthritis receiving methotrexate as first-line therapy: a Swedish observational nationwide study
- Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis
- Utilisation of cardiovascular preventive services in a rheumatoid arthritis population-based cohort
- MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis
- PerIoperative iNflammatory reSponse assessment In hiGH-risk patienTs undergoing non-cardiac surgery (INSIGHT): study protocol of a prospective non-interventional observational study
- Comorbidities and treatment patterns in early rheumatoid arthritis: a nationwide Swedish study
- Mining the pathogenesis of rheumatoid arthritis, the leading role of the environment
- Systematic literature review of observational cohorts and clinical trials into the success rate of glucocorticoid discontinuation after their use as bridging therapy in patients with rheumatoid arthritis
- EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome
- Retinal Microvasculature Alteration in Patients with Rheumatoid Arthritis
- Disease-Modifying Antirheumatic Drugs and Risk of Parkinson Disease: Nested Case-Control Study of People With Rheumatoid Arthritis
- Association of rheumatoid arthritis and high sodium intake with major adverse cardiovascular events: a cross-sectional study from the seventh Korean National Health and Nutrition Examination Survey
- Multimorbidity Accrual After Incident Rheumatoid Arthritis: A Wolf at the Door
- Investigating changes in disease activity as a mediator of cardiovascular risk reduction with methotrexate use in rheumatoid arthritis
- Early-life famine exposure and rheumatoid arthritis in Chinese adult populations: a retrospective cohort study
- Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation
- Burden and trajectory of multimorbidity in rheumatoid arthritis: a matched cohort study from 2006 to 2015
- Heart rate and heart rate variability in patients with chronic inflammatory joint disease: The role of pain duration and the insular cortex
- Inflammaging as a link between autoimmunity and cardiovascular disease: the case of rheumatoid arthritis
- Could Disease Activity Score in 28 Joints-Gamma-glutamyl Transferase Use Improve Cardiovascular Disease Risk Management in Rheumatoid Arthritis?
- Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the association with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting